8 May 2019 - - Australia-based biopharmaceutical company Propanc Biopharma, Inc. (OTCQB: PPCB) has appointed Dr. Ralf Brandt to its scientific advisory board, the company said.

Brandt previously served as an advisory board member to Propanc over a seven-year period between 2011 and 2018.

During this period, he played an instrumental role in advancing Propanc's lead product candidate, PRP, through early stage and formal preclinical development activities.

He is a co-inventor of Propanc's lead patent family and a co-author of a peer reviewed scientific publication, published by Propanc and its research partners. He will provide significant translational research expertise and clinical support advisory support services to the company's drug development pipeline.

Brandt previously stepped down from Propanc's SAB, as he underwent a merger of his cofounded company, vivoPharm, a global oncology and immuno-oncology discovery company providing a range of preclinical services with Cancer Genetics, Inc., a NASDAQ listed company enabling precision medicine in oncology from bench to bedside.

He currently serves as president of Discovery and Early Development of Cancer Genetics.

During Brandt's long career in the pharmaceutical industry, he has acquired significant knowledge and expertise in leading business units and representation of services to the preclinical research market, which includes major global pharmaceutical and biotech companies from around the world.

Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.

The company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.